» Articles » PMID: 7054072

Drugs As Indicators of Hepatic Function

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1982 Jan 1
PMID 7054072
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

It is well recognized that liver disease may influence the disposition of many drugs. Conversely, it has been suggested that knowledge of the disposition of a model drug might provide an index of certain aspects of hepatic function. This review discusses the physiology of drug disposition and indicates how recent progress in understanding the determinants of drug disposition has provided useful indices of individual aspects of hepatic function. Topics which are discussed are the interpretation of pharmacokinetic parameters as indices of hepatic function, including half-life clearance, and intrinsic clearance. Utilizing the "intact hepatocyte hypothesis" as an operational model, an approach is described that uses the pharmacokinetic disposition of high and low intrinsic clearance drugs following p.o. and i.v. administration to provide quantitative estimates of hepatic function, flow to functioning hepatocytes, and the extent of portasystemic shunting through the liver. Thus, the theoretical basis for quantitation of certain aspects of hepatic function are available. It remains to be determined whether these indices will provide clinically useful measures to follow the natural history of hepatic disease.

Citing Articles

Navigation surgery using indocyanine green fluorescent imaging for hepatoblastoma patients.

Souzaki R, Kawakubo N, Matsuura T, Yoshimaru K, Koga Y, Takemoto J Pediatr Surg Int. 2019; 35(5):551-557.

PMID: 30778701 DOI: 10.1007/s00383-019-04458-5.


Fluorescence guided surgery in liver tumors: applications and advantages.

Rossi G, Tarasconi A, Baiocchi G, De Angelis G, Gaiani F, Di Mario F Acta Biomed. 2018; 89(9-S):135-140.

PMID: 30561406 PMC: 6502182. DOI: 10.23750/abm.v89i9-S.7974.


Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.

Baririan N, Van Obbergh L, Desager J, Verbeeck R, Wallemacq P, Starkel P Clin Pharmacokinet. 2007; 46(3):261-70.

PMID: 17328584 DOI: 10.2165/00003088-200746030-00006.


Evaluation of hepatic function in liver cirrhosis: clinical utility of galactose elimination capacity, hepatic clearance of D-sorbitol, and laboratory investigations.

Garello E, Battista S, Bar F, Niro G, Cappello N, Rizzetto M Dig Dis Sci. 1999; 44(4):782-8.

PMID: 10219839 DOI: 10.1023/a:1026678228967.


The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Le Couteur D, McLean A Clin Pharmacokinet. 1998; 34(5):359-73.

PMID: 9592620 DOI: 10.2165/00003088-199834050-00003.